1. ALLA AKTIER
  2. NYHETER
  3. NANEXA

Nanexa

Nyheter Nanexa Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Nanexa publishes annual report for 2024

MARKN.

Nanexa AB (publ) today announces that the annual report for 2024 has been published and is available on the company's website https://nanexa.com/en/financial-reports.

” We have taken major steps during 2024 in the development of our scale formulation for one-month depots.”

“We started 2024 with a strategy focused on three areas. The NEX-22 project, the collaboration with Novo Nordisk and the implementation of a few prioritised partner projects. That strategy has been successful in many ways and we are ending the year strongly. We are proud to have created what we consider to be the first depot formulation of a GLP-1 agonist with month-long release demonstrated in a clinical study. At the same time, the collaboration with our most important partners is progressing well”, says David Westberg, CEO of Nanexa.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ) 
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com

The company’s Certified Adviser is Carnegie Investment Bank AB (publ).

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.

Nanexa’s share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

Nanexa Annual Report 2024

Datum 2025-04-10, kl 09:40
Källa MFN
Bifogade filer
Nanexa Annual Report 2024